Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis.

Weber, S; Pongratz, G; Schneider, M; Brinks, R

Need for improvements in reported cost effectiveness of adalimumab in rheumatoid arthritis.

Weber, S; Pongratz, G; Schneider, M; Brinks, R.

Afiliação

Weber S; Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany.
Pongratz G; Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany.
Schneider M; Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany.
Brinks R; Poliklinik für Rheumatologie, Hiller Research Unit for Rheumatology, Moorenstraße 5, 40225, Düsseldorf, Germany. ralph.brinks@med.uni-duesseldorf.de.

Z Rheumatol ; 76(2): 183-184, 2017 03.

Article em En | MEDLINE | ID: mdl-28084542

Assuntos

Adalimumab; Análise Custo-Benefício; Anticorpos Monoclonais; Antirreumáticos; Artrite Reumatoide; Etanercepte; Humanos; Resultado do Tratamento; Fator de Necrose Tumoral alfa

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Análise Custo-Benefício / Adalimumab Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: Z Rheumatol Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google